tiprankstipranks
Akebia Therapeutics (DE:AX9)
FRANKFURT:AX9
Germany Market
AX9
Akebia Therapeutics
RESEARCH TOOLSreports

Akebia Therapeutics (AX9) Stock Forecast & Price Target

2 Followers
See the Price Targets and Ratings of:

AX9 Analyst Ratings

Moderate Buy
3Ratings
Moderate Buy
2 Buy
1 Hold
0 Sell
Based on 3 analysts giving stock ratings to
Akebia
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AX9 Stock 12 Month Forecast

Average Price Target

€3.18
▲(194.65% Upside)
Based on 3 Wall Street analysts offering 12 month price targets for Akebia Therapeutics in the last 3 months. The average price target is €3.18 with a high forecast of €5.21 and a low forecast of €0.87. The average price target represents a 194.65% change from the last price of €1.08.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"€6","-1":"-€1","0.75":"€0.75","2.5":"€2.5","4.25":"€4.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":5.20728012,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€5.21</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":3.1822267399999995,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€3.18</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":0.86788002,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€0.87</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,0.75,2.5,4.25,6],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.146,1.458406163076923,1.770812326153846,2.0832184892307692,2.395624652307692,2.7080308153846153,3.0204369784615386,3.3328431415384614,3.6452493046153847,3.957655467692308,4.270061630769231,4.582467793846154,4.894873956923077,{"y":5.20728012,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.146,1.302632826153846,1.4592656523076921,1.6158984784615384,1.7725313046153843,1.9291641307692307,2.085796956923077,2.242429783076923,2.3990626092307688,2.555695435384615,2.7123282615384614,2.8689610876923073,3.0255939138461536,{"y":3.1822267399999995,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,1.146,1.1246061553846154,1.1032123107692307,1.0818184661538461,1.0604246215384614,1.0390307769230769,1.0176369323076924,0.9962430876923076,0.974849243076923,0.9534553984615384,0.9320615538461539,0.9106677092307692,0.8892738646153846,{"y":0.86788002,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.148,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.744,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.254,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.86,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.35,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.334,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.147,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.075,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.175,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.131,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.871,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":0.966,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.146,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target€5.21Average Price Target€3.18Lowest Price Target€0.87
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on DE:AX9
Roanna Ruiz
Leerink Partners
Leerink Partners
€0.87
Hold
-19.64%
Downside
Downgraded
08/07/26
Akebia downgraded to Market Perform from Outperform at LeerinkAkebia downgraded to Market Perform from Outperform at Leerink
BTIG Analyst forecast on DE:AX9
Julian Harrison
BTIG
BTIG
€3.47
Buy
221.44%
Upside
Reiterated
08/06/26
Akebia Therapeutics: Strengthening Vafseo Traction and De-Risked VOICE Trial Outcomes Support Buy Rating
H.C. Wainwright Analyst forecast on DE:AX9
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
€5.21
Buy
382.16%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Envista Holdings (NYSE: NVST) and Akebia Therapeutics (NASDAQ: AKBA)
Piper Sandler Analyst forecast on DE:AX9
Allison Bratzel
Piper Sandler
Piper Sandler
€3.47
Buy
221.44%
Upside
Reiterated
04/24/26
Akebia Therapeutics (AKBA) Gets a Buy from Piper Sandler
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Leerink Partners Analyst forecast on DE:AX9
Roanna Ruiz
Leerink Partners
Leerink Partners
€0.87
Hold
-19.64%
Downside
Downgraded
08/07/26
Akebia downgraded to Market Perform from Outperform at LeerinkAkebia downgraded to Market Perform from Outperform at Leerink
BTIG Analyst forecast on DE:AX9
Julian Harrison
BTIG
BTIG
€3.47
Buy
221.44%
Upside
Reiterated
08/06/26
Akebia Therapeutics: Strengthening Vafseo Traction and De-Risked VOICE Trial Outcomes Support Buy Rating
H.C. Wainwright Analyst forecast on DE:AX9
Matthew Caufield
H.C. Wainwright
H.C. Wainwright
€5.21
Buy
382.16%
Upside
Reiterated
08/06/26
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (NYSE: LLY), Envista Holdings (NYSE: NVST) and Akebia Therapeutics (NASDAQ: AKBA)
Piper Sandler Analyst forecast on DE:AX9
Allison Bratzel
Piper Sandler
Piper Sandler
€3.47
Buy
221.44%
Upside
Reiterated
04/24/26
Akebia Therapeutics (AKBA) Gets a Buy from Piper Sandler
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
AVBPArriVent BioPharma, Inc.
BTSGBrightSpring Health Services, Inc.
AMLXAmylyx Pharmaceuticals Inc
TNYATenaya Therapeutics
JBIOJade Biosciences
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Akebia Therapeutics

3 Months
Julian HarrisonBTIG
Success Rate
4/13 ratings generated profit
31%
Average Return
+2.31%
Copying Julian Harrison's trades and holding each position for 3 Months would result in 30.77% of your transactions generating a profit, with an average return of +2.31% per trade.
1 Year
Julian HarrisonBTIG
Success Rate
5/13 ratings generated profit
38%
Average Return
+30.15%
Copying Julian Harrison's trades and holding each position for 1 Year would result in 38.46% of your transactions generating a profit, with an average return of +30.15% per trade.
2 Years
Julian HarrisonBTIG
Success Rate
2/13 ratings generated profit
15%
Average Return
-20.55%
Copying Julian Harrison's trades and holding each position for 2 Years would result in 15.38% of your transactions generating a profit, with an average return of -20.55% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AX9 Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
8
5
5
2
3
Buy
0
0
0
0
0
Hold
0
0
0
0
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
8
5
5
2
4
In the current month, AX9 has received 3 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. AX9 average Analyst price target in the past 3 months is 3.18.
Each month's total comprises the sum of three months' worth of ratings.

AX9 Financial Forecast

AX9 Earnings Forecast

Next quarter’s earnings estimate for AX9 is -€0.03 with a range of -€0.05 to -€0.02. The previous quarter’s EPS was -€0.03. AX9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year AX9 has Performed in-line its overall industry.
Next quarter’s earnings estimate for AX9 is -€0.03 with a range of -€0.05 to -€0.02. The previous quarter’s EPS was -€0.03. AX9 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 46.32% of the time in the same period. In the last calendar year AX9 has Performed in-line its overall industry.

AX9 Sales Forecast

Next quarter’s sales forecast for AX9 is €41.86M with a range of €37.32M to €45.61M. The previous quarter’s sales results were €42.64M. AX9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year AX9 has Performed in-line its overall industry.
Next quarter’s sales forecast for AX9 is €41.86M with a range of €37.32M to €45.61M. The previous quarter’s sales results were €42.64M. AX9 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 31.16% of the time in the same period. In the last calendar year AX9 has Performed in-line its overall industry.

AX9 Stock Forecast FAQ

What is DE:AX9’s average 12-month price target, according to analysts?
Based on analyst ratings, Akebia Therapeutics’s 12-month average price target is 3.18.
    What is DE:AX9’s upside potential, based on the analysts’ average price target?
    Akebia Therapeutics has 194.65% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Akebia Therapeutics a Buy, Sell or Hold?
          Akebia Therapeutics has a consensus rating of Moderate Buy, which is based on 2 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Akebia Therapeutics’s share price target?
            The average share price target for Akebia Therapeutics is 3.18. This is based on 3 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is €5.21 ,and the lowest forecast is €0.87. The average share price target represents 194.65% Increase from the current price of €1.08.
              What do analysts say about Akebia Therapeutics?
              Akebia Therapeutics’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 3 Wall Streets Analysts.
                How can I buy shares of Akebia Therapeutics?
                To buy shares of DE:AX9, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.